FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Magnus Essand

Research Profile

Disorders

Living Beings

Anatomy

Procedures

Chemicals & Drugs

Physiology

Co-author Network

Publications

TOP 3
Magnus Essand; Angelica Loskog
Genetically engineered T cells for the treatment of cancer.
Munitta Muthana; Samuel Rodrigues; Simon Tazzyman; Abigail Welford; Yung-Yi Chen; Magnus Essand; Russell Hughes; Fiona Morrow; Claire E Lewis
Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.
Di Yu; Rachel Adamson; Xiaolong Fan; Karin Forsberg-Nilsson; Chuan Jin; Olle Korsgren; Katarina Le Blanc; Norman Maitland; Berith Nilsson; Mohanraj Ramachandran; Lene Uhrbom; Bengt Westermark; Jing Xu; Magnus Essand
Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Magnus Essand (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Magnus Essand; Angelica Loskog
Genetically engineered T cells for the treatment of cancer.
Journal of internal medicine 2013;273(2):166-81.
2013: Munitta Muthana; Samuel Rodrigues; Simon Tazzyman; Abigail Welford; Yung-Yi Chen; Magnus Essand; Russell Hughes; Fiona Morrow; Claire E Lewis
Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.
Cancer research 2013;73(2):490-5.
2013: Di Yu; Rachel Adamson; Xiaolong Fan; Karin Forsberg-Nilsson; Chuan Jin; Olle Korsgren; Katarina Le Blanc; Norman Maitland; Berith Nilsson; Mohanraj Ramachandran; Lene Uhrbom; Bengt Westermark; Jing Xu; Magnus Essand
Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.
PloS one 2013;8(1):e54952.
2013: Christian Molnár; Gunnar Tufveson; Lars Wennberg; Christian Berne; Magnus Essand; Erik Larsson; Olle Korsgren
Islet engraftment and revascularization in clinical and experimental transplantation.
Cell transplantation 2013;22(2):243-51.
2013: Magnus Essand
Virotherapy of neuroendocrine tumors.
Neuroendocrinology 2013;97(1):26-34.
2012: Victoria Hillerdal; Berith Nilsson; Björn Carlsson; Fredrik Eriksson; Magnus Essand
T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(39):15877-81.
2012: Lars A Forsberg; Vilmantas Giedraitis; Jennifer R Harris; Martin Ingelsson; Carlos Iribarren; Lars Lannfelt; Robert Lyle; Frederick W Miller; Terrance P O'Hanlon; Geeta Pakalapati; Nancy L Pedersen; Arkadiusz Piotrowski; Chiara Rasi; Hamid R Razzaghian; Lisa G Rider; Anna Ronowicz; Eric Strachan; Krista Stanton Thilbeault; Hemant K Tiwari; Lindsay Waite; Maxwell P Westerman; Nathan E Wineinger; Devin Absher; Themistocles L Assimes; dorret boomsma; Fredrik Eriksson; Magnus Essand; Jan P Dumanski
Age-related somatic structural changes in the nuclear genome of human blood cells.
American journal of human genetics 2012;90(2):217-28.
2012: R E Adamson; R Birnie; K F Chambers; A Dhawan; Magnus Essand; H Evans; A A Frazier; R R Mitry; E Schenk; Norman J Maitland
In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus.
Human gene therapy 2012;23(2):218-30.
2012: Moa Fransson; Robert A Harris; Eva Brittebo; Joachim Burman; Magnus Essand; Binfeng Lu; Peetra U Magnusson; Berith Nilsson; Elena Piras; Angelica Loskog
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.
Journal of neuroinflammation 2012;9():112.
2011: Di Yu; Fredrik Eriksson; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Magnus Essand
Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.
Journal of virology 2011;85(24):13114-23.
2011: Magnus Essand; Valeria Giandomenico; J Leja; Kjell E Oberg
Oncolytic viruses for the treatment of neuroendocrine tumors.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2011;43(12):877-83.
2011: J Leja; Bo Nilsson; Kjell Oberg; D Yu; A Zieba; Göran Akerström; Lars Gedda; Valeria Giandomenico; T Hakkarainen; Magnus Essand
Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.
Gene therapy 2011;18(11):1052-62.
2011: Munitta Muthana; Athina Giannoudis; Simon D Scott; Hsin-Yu Fang; Seth B Coffelt; Fiona J Morrow; Craig Murdoch; Julian Burton; Neil Cross; Bernard Burke; Roshna Mistry; Freddie C Hamdy; Nicola J Brown; Lindsay Georgopoulos; Peter Hoskin; Magnus Essand; Claire E Lewis; Norman J Maitland
Use of macrophages to target therapeutic adenovirus to human prostate tumors.
Cancer research 2011;71(5):1805-15.
2011: Angelika Danielsson; Helena Dzojic; Victoria Rashkova; Wing-Shing Cheng; Magnus Essand
The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication.
PloS one 2011;6(2):e14700.
2010: Norman J Maitland; Karen Chambers; Lindsay Georgopoulos; Martha Simpson-Holley; Regina Leadley; Helen Evans; Magnus Essand; Angelika Danielsson; Wytske van Weerden; Corrina de Ridder; Robert Kraaij; Chris H Bangma
Gene transfer vectors targeted to human prostate cancer: do we need better preclinical testing systems?
Human gene therapy 2010;21(7):815-27.
2010: Ellen Schenk; Magnus Essand; Chris H Bangma; Chris Barber; Jean-Paul Behr; Simon Briggs; Robert Carlisle; Wing-Shing Cheng; Angelika Danielsson; Iris J C Dautzenberg; Helena Dzojic; Patrick Erbacher; Kerry Fisher; April Frazier; Lindsay J Georgopoulos; Rob Hoeben; Stefan Kochanek; Daniela Koppers-Lalic; Robert Kraaij; Florian Kreppel; Leif Lindholm; Maria Magnusson; Norman Maitland; Patrick Neuberg; Berith Nilsson; Manfred Ogris; Jean-Serge Remy; Michelle Scaife; Erik Schooten; Len Seymour; Thomas Totterman; Taco G Uil; Karel Ulbrich; Joke L M Veldhoven-Zweistra; Jeroen de Vrij; Wytske van Weerden; Ernst Wagner; Ralph Willemsen
Clinical adenoviral gene therapy for prostate cancer.
Human gene therapy 2010;21(7):807-13.
2010: A Danielsson; Graciela Elgue; B M Nilsson; Bo Nilsson; John D Lambris; Thomas H Tötterman; S Kochanek; F Kreppel; Magnus Essand
An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood.
Gene therapy 2010;17(6):752-62.
2010: Justyna Leja; Berith Nilsson; Di Yu; Elisabet Gustafson; Göran Akerström; Kjell Oberg; Valeria Giandomenico; Magnus Essand
Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability.
PloS one 2010;5(1):e8916.
2009: Justyna Leja; Ahmed Essaghir; Magnus Essand; Kenneth Wester; Kjell Oberg; Thomas H Tötterman; Ricardo Lloyd; George Vasmatzis; Jean-Baptiste Demoulin; Valeria Giandomenico
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2009;22(2):261-72.
2009: Sofia Vikman; Roberta Sommaggio; Manuel de la Torre; Kjell Oberg; Magnus Essand; Valeria Giandomenico; Angelica Loskog; Thomas H Totterman
Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue.
Acta oncologica (Stockholm, Sweden) 2009;48(3):391-400.
2009: Ole Forsberg; Björn Carlsson; Per-Uno Malmstrom; Gustav Ullenhag; Thomas H Tötterman; Magnus Essand
High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
The Prostate 2009;69(1):70-81.
2008: Ole Forsberg; Björn Carlsson; Thomas H Tötterman; Magnus Essand
Strategic use of an adenoviral vector for rapid and efficient ex vivo-generation of cytomegalovirus pp65-reactive cytolytic and helper T cells.
British journal of haematology 2008;141(2):188-99.
2008: A Danielsson; Helena Dzojic; Bo Nilsson; Magnus Essand
Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region.
Cancer gene therapy 2008;15(4):203-13.
2008: Sofia Vikman; Valeria Giandomenico; Roberta Sommaggio; Kjell Oberg; Magnus Essand; Thomas H Tötterman
CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients.
Cancer immunology, immunotherapy : CII 2008;57(3):399-409.
2008: Sara Mangsbo; Christina Ninalga; Magnus Essand; Angelica Loskog; Thomas H Tötterman
CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(1):34-42.
2007: Justyna Leja; Helena Dzojic; Elisabet Gustafson; Kjell Oberg; Valeria Giandomenico; Magnus Essand
A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2455-62.
2007: Björn Carlsson; Ole Forsberg; Mats Bengtsson; Thomas H Tötterman; Magnus Essand
Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy.
The Prostate 2007;67(4):389-95.
2007: Helena Dzojic; Wing-Shing Cheng; Magnus Essand
Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model.
Cancer gene therapy 2007;14(3):233-40.
2006: Helena Dzojic; Angelica Loskog; Thomas H Tötterman; Magnus Essand
Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
The Prostate 2006;66(8):831-8.
2006: Wing-Shing Cheng; Helena Dzojic; Berith Nilsson; Thomas H Tötterman; Magnus Essand
An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer.
Cancer gene therapy 2006;13(1):13-20.
2005: Magnus Essand; Sofia Vikman; Jan Grawé; Lars Gedda; Carina Hellberg; Kjell Oberg; Thomas H Totterman; Valeria Giandomenico
Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1.
Journal of molecular endocrinology 2005;35(3):489-501.
2005: Björn Carlsson; Mingyan Hou; Valeria Giandomenico; Berith Nilsson; Thomas H Totterman; Magnus Essand
Simultaneous generation of cytomegalovirus-specific CD8+ and CD4+ T lymphocytes by use of dendritic cells comodified with pp65 mRNA and pp65 protein.
The Journal of infectious diseases 2005;192(11):1912-20.
2005: Thomas H Totterman; Angelica Loskog; Magnus Essand
The immunotherapy of prostate and bladder cancer.
BJU international 2005;96(5):728-35.
2005: Magnus Essand
Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.
Acta oncologica (Stockholm, Sweden) 2005;44(6):610-27.
2005: Sofia Vikman; Magnus Essand; Janet L Cunningham; Manuel de la Torre; Kjell Oberg; Thomas H Tötterman; Valeria Giandomenico
Gene expression in midgut carcinoid tumors: potential targets for immunotherapy.
Acta oncologica (Stockholm, Sweden) 2005;44(1):32-40.
2005: Christina Ninalga; Angelica Loskog; Magdalena Klevenfeldt; Magnus Essand; Thomas H Tötterman
CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(1):20-7.
2004: Björn Carlsson; Thomas H Tötterman; Magnus Essand
Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP.
The Prostate 2004;61(2):161-70.
2004: Wing-Shing Cheng; Robert Kraaij; Berith Nilsson; Laura van der Weel; Corrina M A de Ridder; Thomas H Tötterman; Magnus Essand
A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;10(2):355-64.
2004: Angelica Loskog; Helena Dzojic; Sofia Vikman; Christina Ninalga; Magnus Essand; Olle Korsgren; Thomas H Totterman
Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(11):7200-5.
2003: Wing-Shing Cheng; Valeria Giandomenico; Ira Pastan; Magnus Essand
Characterization of the androgen-regulated prostate-specific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter.
Endocrinology 2003;144(8):3433-40.
2003: Björn Carlsson; Wing-Shing Cheng; Thomas H Tötterman; Magnus Essand
Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators.
British journal of haematology 2003;121(3):428-38.